BioMarin Pharmaceuticals Inc (BMRN): Today's Featured Health Care Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

BioMarin Pharmaceuticals (BMRN) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day down 0.2%. By the end of trading, BioMarin Pharmaceuticals rose 46 cents (1.2%) to $37.48 on average volume. Throughout the day, 1.4 million shares of BioMarin Pharmaceuticals exchanged hands as compared to its average daily volume of 1.7 million shares. The stock ranged in a price between $36.97-$37.82 after having opened the day at $37.05 as compared to the previous trading day's close of $37.02. Other companies within the Health Care sector that increased today were: Astex Pharmaceuticals (ASTX), up 15.4%, Response Genetics (RGDX), up 14.3%, Catalyst Pharmaceutical Partners (CPRX), up 13.1%, and Tengion (TNGN), up 13%.

• ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and rest of the world. BioMarin Pharmaceuticals has a market cap of $4.7 billion and is part of the drugs industry. Shares are up 10.4% year to date as of the close of trading on Monday. Currently there are 14 analysts that rate BioMarin Pharmaceuticals a buy, no analysts rate it a sell, and three rate it a hold.

TheStreet Ratings rates BioMarin Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity.

• You can view the full BioMarin Ratings Report.

On the negative front, ImmunoCellular Therapeutics (IMUC), down 16.5%, Palatin Technologies (PTN), down 8.9%, Chembio Diagnostics (CEMI), down 8.8%, and Graymark Healthcare (GRMH), down 7.6%, were all laggards within the health care sector with HCA Holdings (HCA) being today's health care sector laggard.

• Use our health care section to find sector-relevant news.
• Or find some new ideas from our top rated stocks lists.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR (XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care (RXD).

• Find other investment ideas from our top rated ETFs lists.

For more information on Biomarin Pharmaceutical Inc. click any of the following:

• Biomarin Pharmaceutical Inc. Stock Price

• Biomarin Pharmaceutical Inc. Analyst Ratings

• Biomarin Pharmaceutical Inc. Key Stats & Profile

• Biomarin Pharmaceutical Inc. Earnings

• Biomarin Pharmaceutical Inc. Ratio Comparison

• Biomarin Pharmaceutical Inc. Growth Rates

• Biomarin Pharmaceutical Inc. Balance Sheet

• Biomarin Pharmaceutical Inc. Cash Flow

• Biomarin Pharmaceutical Inc. Income Statement